Abstract
Age is a major risk factor for cardiovascular associated diseases which are leading causes of death
globally. Accordingly, 80% of all cardiovascular deaths occurred in patients aged 65 and over. Endothelial cell
senescence, characterized by cell cycle arrest and a senescence-associated secretory phenotype (SASP), is a
major contributor to age related cardiovascular dysfunction. However, the mechanism by which endothelial
cells are subjected to senescence is still unclear.
We have recently made novel findings that endothelial cell HSPA12B deficient (eHSPA12B-/-) mice exhibit
cardiac endothelial cell senescence accompanied by severe cardiac hypertrophy, fibrosis, and persistent
inflammation when compared with age- and gender-matched WT controls. Our findings suggest that senescent
endothelial cells play an important role in the regulation of cardiac hypertrophy and fibroblast activation and
that endothelial cell HSPA12B limits senescence of endothelial cells. Therefore, understanding the
mechanisms by which HSPA12B regulates endothelial cell senescence would be important for seeking an
approach to prevent or reverse senescent endothelial cells, thus reducing age-related cardiovascular disease.
To elucidate how HSPA12B limits senescence of endothelial cells, we examined the effect of HSPA12B on
ATF6 (Activating transcription factor 6) transcriptional activity and its target gene MANF (Mesencephalic
Astrocyte Derived Neurotrophic Factor) expression. ATF6 is an important transcriptional factor that regulates
the expression of genes involved in proper protein folding and cellular senescence. MANF is an evolutionarily
conserved protective modulator for the maintenance of tissue immune and metabolic homeostasis.
Interestingly, we observed that HSPA12B is critical for sustaining ATF6 transcriptional activity and MANF
expression. The data suggest that ATF6 and MANF may be involved in the HSPA12B mediated protective
effect on endothelial cell senescence.
To investigate how endothelial cell senescence contributes to cardiac hypertrophy, we examined cardiac
mitochondrial glucose oxidation (MGO) which is one of the major contributors to myocardial energy production.
Compromised mitochondrial glucose oxidation leads to the development of cardiac hypertrophy and eventually
heart failure. We observed that eHSPA12B-/- resulted in decreased Acetyl-CoA and increased lactate
accumulation. The data indicate that eHSPA12B-/- impairs cardiac mitochondrial glucose oxidation. Our
observation also suggests that senescent endothelial cells induce cardiac hypertrophy via impairment of
cardiac myocyte MGO (mitochondrial glucose oxidation).
To address how endothelial cell senescence impairs cardiac MGO, we induced endothelial cell senescence
by ETO (etoposide), collected the medium as the senescent conditioned medium (SCM), and treated adult
cardiac myocytes with the SCM. We observed that SCM promotes metabolic reprogramming from glucose
oxidation to glycolysis in adult cardiac myocytes by increasing PDK4 (Pyruvate Dehydrogenase Kinase 4) and
decreasing TFAM (Mitochondrial transcription factor A). PDK4 is a key enzyme in the regulation of glucose
oxidation by inhibiting the conversion of pyruvate into Acetyl-CoA via promoting PDH phosphorylation and
inactivation. TFAM is a core mitochondrial transcription factor for mitochondrial biogenesis by regulating
mtDNA replication and transcription.
This application is to decipher the role of HSPA12B in age-related endothelial cell senescence and how
endothelial cell senescence results in cardiac hypertrophy and dysfunction. Based on our novel findings, we
hypothesize that: i) HSPA12B limits endothelial cell senescence is mediated by activation of ATF6/MANF
signaling and that; ii) endothelial cell senescence contributes to cardiac hypertrophy and dysfunction via
impaired mitochondrial glucose oxidation in cardiomyocytes. To critically evaluate this hypothesis, we propose
the following specific aims. Aim 1. Define the mechanisms by which HSPA12B regulates ATF6 transcriptional
activity and limits endothelial cell senescence. Aim 2. Investigate the role of endothelial cell senescence in
age-related cardiac hypertrophy and its underlying mechanisms.
Successful completion of the proposed studies will result in a wealth of novel data showing the novel role
of HSPA12B mediated ATF6 in the regulation of endothelial cell senescence. The senescent endothelial cells
contribute to age-related cardiac metabolic disorders and hypertrophy. These new findings will be the basis for
the development of innovative therapies for age-related cardiomyopathy.